M923

BIOLOGICAL3 trials

Sponsors

Momenta Pharmaceuticals, Inc.

Conditions

Chronic Plaque PsoriasisHealthyPsoriasisRheumatoid Arthritis

Phase 1

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

CompletedNCT02675023

Momenta Pharmaceuticals, Inc.Healthy

Start: 2016-01-31End: 2016-07-31Updated: 2019-10-15

Phase 3

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

CompletedNCT02581345

Momenta Pharmaceuticals, Inc.Chronic Plaque Psoriasis, Psoriasis

Start: 2015-09-30End: 2017-04-04Updated: 2018-10-17

Usability of an AI for M923 in Subjects With Moderate to Severe RA

CompletedNCT02722044

Momenta Pharmaceuticals, Inc.Rheumatoid Arthritis

Start: 2016-04-30End: 2017-02-21Updated: 2018-05-16

Related Papers

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the Rheumatic Diseases2018-03-07112 citations